MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain

About this update from Mira Pharmaceuticals, Inc.

Optimized Oral Formulation Demonstrates Favorable Oral Bioavailability Together with Robust Brain and Liver Distribution Following Oral Administration MIAMI, FL / ACCESS Newswire / July 10, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company") , a clinical-stage pharmaceutical company, today announced positive results from preclinical studies evaluating optimized oral formulations of MIRA-55, the Company's oral drug candidate being developed as a non-opioid therapy for chronic inflammatory pain. Following evaluation of multiple oral formulations, the Company selected a lead formulation demonstrating favorable oral bioavailability together with sustained systemic exposure and reproducible distribution into both brain and liver tissue following oral administration. Collectively, these findings support the continued development of MIRA-55 as an orally administered therapy for chronic inflammatory pain. "Patients deserve safer and more effective non-opioid treatment options for chronic inflammatory pain," said Erez Aminov, Chief Executive Officer of MIRA Pharmaceuticals. "These formulation and pharmacokinetic findings represent another important step in advancing MIRA-55 as a differentiated oral therapy designed to address that need." The objective of the study was to optimize the oral formulation of MIRA-55 by comparing multiple formulations in a preclinical pharmacokinetic study. An intravenous reference arm was included to characterize absolute oral bioavailability and support selection of the lead formulation based on its overall pharmacokinetic profile. The selected formulation demonstrated reproducible distribution into both brain and liver tissue following oral administration. Brain exposure may support modulation of central pain-processing pathways, while peripheral distribution may contribute to the anti-inflammatory activity previously observed in MIRA's preclinical efficacy studies. Together, these findings demonstrate that the optimized formulation successfully delivers MIRA-55 to pharmacologically relevant tissues associated with both central and peripheral mechanisms of chronic inflammatory pain. "Formulation optimization is far more than a pharmaceutical exercise-it is what enables a molecule to consistently engage its intended biological targets," said Itzchak Angel, Ph.D., Chief Scientific Advisor of MIRA Pharmaceuticals. "The combination of favorable oral exposure together with reproducible brain and peripheral tissue distribution provides important support for MIRA-55's proposed mechanism of action and its continued development as an oral therapy for chronic inflammatory pain."

View stock analysis, news, and events for Mira Pharmaceuticals, Inc.